Kanvas Biosciences Launches New GMP Lab to Unite Innovation and Scale in Microbiome Drug Development

Partnering with world‑changing companies means seeing them push boundaries and set new benchmarks, time and again. Last year, Kanvas Biosciences made the critical transition from highly scalable lab-based R&D to clinical manufacturing. Now, they’ve taken another leap forward with the announcement of their new Good Manufacturing Practices (GMP) facility in South San Francisco.

This purpose-built, 4,000-square-foot lab will produce clinical-grade live biotherapeutic products (LBPs) under fully anaerobic conditions, from the earliest material to the final encapsulated drug product. By integrating advanced manufacturing alongside their proprietary spatial imaging technology, Kanvas can maintain the integrity, viability, and stability of complex microbial consortia in ways unmatched in the industry.

Beyond powering their own clinical pipeline, Kanvas envisions this capability as a sector-wide resource, enabling partnerships and helping solve long-standing CMC (chemistry, manufacturing, and controls) challenges in the microbiome field. Their insight that process development must go hand-in-hand with product design is a principle we see across hard tech sectors: early foresight in manufacturing is key to accelerating commercialization and ensuring quality at scale.

For Pangaea, this milestone reinforces why we invest in hard tech leaders, companies that don’t just innovate in the lab, but transform the infrastructure, processes, and industry standards that drive lasting impact for planetary and human health.

Read their full announcement on LinkedIn here.